Studies in line with the previously formulated inclusion criteria investigating the efficacy of bDMARDs specifically targeting IL-6 pathway in patients with ANCA-associated vasculitis, remitting seronegative symmetric synovitis with pitting oedema (RS3PE), refractory relapsing polychondritis, TNF-receptor associated periodic fever syndrome (TRAPS) or chronic infantile neurological cutaneous and articular (CINCA) syndrome were not available, as the body of evidence was limited to case reports. Here, IL6 is linked to TNF receptor 1-associated periodic fever syndrome.